1）Impact of divergent effects of astaxanthin on Insulin Signaling in L6 cells.
Ishiki M, Nishida Y, Ishibashi H, Wada T, Fujisaka S, Takikawa A, Urakaze M, Sasaoka T, Usui I, Tobe K.
Endocrinology, 154: 2600-2612, 2013.

2）Cilostazol ameliorates systemic insulin resistance in diabetic db/db mice by suppressing chronic inflammation in adipose tissue via modulation of both adipocyte and macrophage functions.
Wada T, Onogi Y, Kimura Y, Nakano T, Fusanobori H, Ishii Y, Sasahara M, Tsuneki H, Sasaoka T.
Eur J Pharmacol, 707: 120-129, 2013.

3）Hypothalamic orexin prevents hepatic insulin resistance induced by social defeat stress in mice.
Tsuneki H, Tokai E, Sugawara C, Wada T, Sakurai T, Sasaoka T.
Neuropeptides, 47: 213-219, 2013.

4）Rational design and synthesis of 4-substituted 2-pyridin-2-ylamides with inhibitory effects on SH2 domain-containing inositol 5'-phosphatase 2 (SHIP2).
Ichihara Y, Fujimura R, Tsuneki H, Wada T, Okamoto K, Gouda H, Hirono S, Sugimoto K, Matsuya Y, Sasaoka T, Toyooka N.
Eur J Med Chem, 62: 649-660, 2013.

5）Protective effects of coenzyme Q10 against angiotensin II-induced oxidative stress in human umbilical vein endothelial cells.
Tsuneki H, Tokai E, Suzuki T, Seki T, Okubo K, Wada T, Okamoto T, Koya S, Kimura I, Sasaoka T.
Eur J Pharmacol, 701: 218-227, 2013.

6）SH2-containing inositol 5'-phosphatase 2 selectively impairs hypothalamic insulin signalling and regulation of food intake in mice.
Ichihara Y, Wada T, Soeda Y, Ishii Y, Sasahara M, Tsuneki H, Sasaoka T.
J Neuroendocrinol, 25: 372-382, 2013.

7）Eplerenone ameliorates the phenotypes of metabolic syndrome with NASH in liver-specific
SREBP1c Tg mice fed high-fat and high-fructose diet.
Wada T, Miyashita Y, Sasaki M, Aruga Y, Nakamura Y, Ishii Y, Sasahara M, Kanasaki K, Kitada M, Koya D, Shimano H, Tsuneki H, and Sasaoka T.
Am J Physiol Endocrinol Metab, 305: E1415-E1425, 2013.

8）New insigfts into metabolic regulation via bifurcated function of estrogen receptor α.
Wada T, Tsuneki H, and Sasaoka T.
Diabetes, 62: 3996-3998, 2013.